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Abstract
• As of 2015, 9.4% of the US population had a diagnosis of Diabetes Mellitus (DM).
Although most of the data sets studied encompass type 1 (T1) and type 2 (T2)
DM data in all ages of patients, the focus of this project will be on T1DM.
• There are effective methods currently available for the management of T1DM
patients. These methods include: closed-loop insulin pumps that integrate a
continuous glucose monitor (CGM) and insulin pump into one effective system
that calculates the needed insulin doses through complicated algorithms, CGM
with self-blood glucose monitoring calibrations (SBGM) and insulin
administration, and SBGM with insulin administration.
• Literature reveals that closed-loop insulin pumps have the potential to provide
better disease management and improved disease outcomes for those patients
who are motivated to use them as directed and find them a desirable option.

Research Questions
•Will closed-loop insulin pumps provide better efficacy by
monitoring glycemic control according to patient’s blood
glucose levels and glycosylated hemoglobin levels
(HgbA1C) and decrease the incidence of hypoglycemic
episodes, as compared to the current standard treatment
of insulin pump therapy in patients with T1DM?

Discussion
• Historical studies show that an intensive insulin regimen along with strict
monitoring of blood glucose and HgbA1C levels provide patients with less long-term
microvascular side effects of retinopathy, neuropathy, and nephropathy, as well as
the macrovascular side effects of cardiovascular, peripheral vascular and
cerebrovascular disease.
• The DCCT performed by Nathan, et al. (2013) demonstrated a drop of nearly ~2.5% in
HgbA1C and a slowed rate of loss in C-peptide responsiveness in Beta cell
preservation. The EDIC performed by Nathan, et al. (2013) demonstrated the need
for earlier intervention in T1DM by showing that it can reduce severe renal
impairment by ~50%, risk of primary CVD outcomes by 42%, and nonfatal MI or
stroke by 58%.

•What are the unique benefits of the different effective
T1DM management methods?

Applicability to Clinical Practice
• Initial management of a T1DM patient should include basic disease education,
demonstration of SBGM, insulin administration, how to recognize and treat a
hypoglycemic episode, and how to measure either blood or urine ketone
concentration. This will require a multidisciplinary team that should ideally include an
endocrinologist, a certified nurse educator, dietitian, and possibly a mental-health
professional to provide support if the need should arise.
• As potential future family practice providers, we must consider our patient’s lifestyle,
education level, cognition, desire for disease control, and socioeconomic status to
adequately make a choice for their T1DM management regimen.
• SBGM and insulin injections are relatively inexpensive, whereas newer technology is
initially more expensive, but provide better efficacy and ease of use and also a
decrease in hypoglycemic events and hospitalizations. Clinicians must be mindful of
what type of insulin delivery system that they are recommending for each patient.

• When patients can effectively manage their blood glucose, and practice healthy
lifestyle and dietary choices, they can avoid unnecessary hospitalizations and
long-term diabetic complications. This will simultaneously reduce healthcarerelated costs, increase longevity and can improve the patient’s quality of life.

Introduction
• According to the CDC, DM affects 30.3 million people in the US. Five percent of
those cases are estimated to be Type 1 Diabetes Mellitus (T1DM), and the
incidence of DM is steadily increasing with an estimated 1.5 million new cases of
diabetes diagnosed in 2015 alone.

•What are the challenges of these management methods
and how will they affect their actual use-effectiveness?

• Closed-loop systems have proven themselves effective; and can lessen disease burden
on the patient’s lifestyle. They are appropriate to prescribe for use in patients that can
manage them efficiently and are motivated to do so. Closed-loop systems should be
strongly considered as a long-term management method in patients with T1DM.

Literature Review
• The DCCT performed by Nathan, D. M., Bayless, M., Cleary, P., Glenuth, S., GubitosiKlug, R., Lachin, J. M., ... Zinman, B. (2013)showed an improvement in the INT group
with the following outcomes: HgbA1C - by three to six months to a level of 6.9% from
the initial 9.1% . Microvascular – results found were consistent, significant, and clinically
meaningful. Cardiovascular – the patient population was generally too young and
healthy to experience major CVD events (p= 0.059) INT group with three events in
three subjects vs. CONV with twenty-one events in nine subjects. Beta cell preservation
– INT group slowed the rate of loss of C-peptide responsiveness by ~50%.

Table adapted from Beck, et al, 2017 https://doi.org/doi:10.1001/jama.2016.19975

• Devries (2017) reports results from a randomized crossover trial comparing day-andnight closed-loop insulin delivery with usual pump therapy (four weeks each) in 29
adults with well controlled T1DM (HgbA1C <7.5%). A closed-loop system was used, in
which the participant determined the amount of insulin administered before each
meal. Participants had sensor glucose concentration in target range (3.9–10.0 mmol/L)
65.6% (SD 8.1) of the time during usual pump therapy and 76.2% (SD 6.4) of the time
during closed-loop delivery which showed that the closed-loop system increased the
proportion of time when glucose concentration was in target range by 10.5 percentage
points (95% CI 7.6–13.4; p<0.001). Compared with usual pump therapy, closed-loop
delivery reduced mean glucose concentration by 0.4 mmol/L (0.1–0.7, p=0.0226); the
proportion of time with glucose concentration above 10.0 mmol/L by 6.9 percentage
points (3.5–10.2; p=0.0003) and below 3.9 mmol/L by 50% (37–59, p<0.001); and
glycemic dispersion (ie, SD of glucose concentration) by 0.5 mmol/L (0.3–0.7, p<0.001).

Insulin Pump . (2018). [Graphic illustration NIH, US Dept of Health March 5,
2018The National Institute of Health. Retrieved from
https://medlineplus.gov/ency/imagepages/18035.htm].
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Statement of the Problem
• Current medical treatment for diabetic patients require self-blood glucose
monitoring, this monitoring is done using self-blood glucose monitors (SBGM),
which results in many finger sticks.
• Insulin injections can be performed by the patient or by an insulin pump that
must be manually programmed, which requires the patient to be proficient
calculating insulin doses independently. There is a high potential for error
related to insulin administration due to incorrect calibration of the glucometer
or basic human error.
• When patients practice good blood glucose management they can avoid
unnecessary hospitalizations and other diabetic complications, which will
simultaneously reduce healthcare-related costs. These choices should be based
on scientific evidence of effectiveness, not unreliable reports and should be
made after considering the patient’s lifestyle and its’ impact on each method’s
particular benefits and challenges.

Common Risk Factors for Diabetic Complications
2011-2014, US adults >18 years of age with diagnosed diabetes, [95% CI]
Smoking

smoking at least 100 cigarettes in their lifetime.

BMI

87.5% were overweight or obese, defined as a BMI of 25 or greater; 26.1% having a BMI
of 25-30, 43.5% having a BMI of 30-40, and 17.8% with a BMI of 40 or higher.

Physical Inactivity 40.8% of adults got less than 10 minutes/week of moderate to vigorous activity in
either work, leisure, or transportation.

Hypertension

73.6% had systolic BP of 140mmHg or higher and diastolic BP of 90mmHg or higher, or
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they were already on BP controlling medications.

High Cholesterol
• The CDC (2017) states that In 2014, a total of 7.2 million hospital discharges and
14.2 million emergency department visits were reported with diabetes being
listed as any kind of diagnosis among US adults aged 18 years or older. The
total direct and indirect estimated cost of diagnosed diabetes in the US in 2012
was $245 billion; with an average of $13,700/year/person being medical
expenditures related to diabetes. This is around 2.3 times higher than
expenditures for people without diabetes. It is also important to note that DM
was the seventh leading cause of death in the US in 2015.

15.9% were current smokers and 34.5% had quit smoking but had a history of

58.2% over age 21 with no self-reported CV disease who were eligible for statin therapy
and were on a lipid-lowering medication. 66.9% over age 21 with self-reported CV
disease who were eligible for statin therapy and were on a lipid-lowering medication.

Hyperglycemia

15.6% of adults had a HgbA1C value higher than 9%.

Center for Disease Control and Prevention. (2017). The National Diabetes Statistics Report [Data file]. Retrieved
from https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf

Table adapted from Battelino, Omladic, and Phillip 2015 from https://doi.org/10.1016/j.beem.2015.03.001
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